Anthony Bell, | |
6775 Point Pleasant Rd, Millwood, WV 25262-8100 | |
(304) 273-0112 | |
(304) 273-0115 |
Full Name | Anthony Bell |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 6775 Point Pleasant Rd, Millwood, West Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1396103578 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Anthony Bell, Po Box 470, Point Pleasant, WV 25550-0470 Ph: (304) 273-0112 | Anthony Bell, 6775 Point Pleasant Rd, Millwood, WV 25262-8100 Ph: (304) 273-0112 |
News Archive
Researchers at Osaka University have developed a computer method that uses magnetic resonance imaging (MRI) and machine learning to rapidly forecast genetic mutations in glioma tumors, which occur in the brain or spine. The work may help glioma patients to receive more suitable treatment faster, giving better outcomes.
Massachusetts Gov. Deval Patrick asked the state legislature to grant his administration broad new authority to "review and reject" excessive rates charged by medical providers in hopes of curbing costs and making health care more affordable, The Boston Globe reports. Under a bill filed Wednesday by Patrick, the rates that "hospitals and other health providers charge insurers would be 'presumptively disapproved as excessive' if they increased faster than the level of medical inflation, and they could be rejected after a public hearing."
Emerging Healthcare Solutions, Inc.. The U.S. drug industry fended off price curbs and other hefty restrictions in The President's health care law even as it prepares for plenty of new business when an estimated 32 million uninsured Americans gain health coverage. Lobbyists beat back proposals to allow importation of low-cost medicines and to have Medicare negotiate drug prices with companies.
Ardea Biosciences, Inc. has announced positive results from a Phase 1 study in normal, healthy volunteers of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and a pilot Phase 2a proof-of-concept study in gout patients of RDEA594's prodrug, RDEA806 (RDEA806 is converted to RDEA594 in the body).
› Verified 2 days ago